Gamma-globin promoter epigenetic state (HBG promoter state)

The epigenetic chromatin state at the γ-globin (HBG1 and HBG2) promoters is a critical regulatory mechanism governing the transition from fetal to adult hemoglobin, a process known as hemoglobin switching (Stamatoyannopoulos, 2005). In adults, these promoters are typically maintained in a repressed, heterochromatic state characterized by high DNA methylation and specific repressive histone marks, such as H3K27me3, which are mediated by complexes like NuRD and proteins like BCL11A and ZBTB7A (Bauer & Orkin, 2015). Reactivating γ-globin expression by altering this chromatin state to a more open, euchromatic configuration is a primary therapeutic strategy for treating β-hemoglobinopathies, including sickle cell disease and β-thalassemia (Makala et al., 2013). Pharmacological interventions target the enzymes responsible for maintaining this repression, such as DNA methyltransferases (DNMTs), histone deacetylases (HDACs), and lysine-specific demethylase 1 (LSD1). By inducing the production of fetal hemoglobin (HbF), these treatments can compensate for defective or absent adult β-globin, thereby reducing the polymerization of sickle hemoglobin and improving red blood cell survival (Esrick et al., 2021). This target represents a focal point for both small-molecule drug development and advanced gene-editing therapies aimed at permanent HbF induction.

Other names

HBG1 promoterHBG2 promoterFetal hemoglobin regulatory regionγ-globin promoter chromatinHbF promoter

The primary mechanism involves the conversion of the γ-globin promoter from a transcriptionally silent, condensed chromatin state (heterochromatin) to an active, open state (euchromatin). This is achieved through the inhibition of DNA methyltransferases (DNMTs) to reduce CpG methylation, the inhibition of histone deacetylases (HDACs) to increase histone acetylation, or the disruption of repressor complexes like NuRD and transcription factors such as BCL11A and ZBTB7A that actively recruit these modifying enzymes to the promoter region.